Randomised Controlled Trial Of Early Intervention To Improve Sexual And Couple Functioning After Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$405,000.00
Summary
Treatment for localised prostate cancer has a long term negative impact on the sexuality, quality of life, and relationship quality of Australian men and their intimate partners. This study will trial a remote access couples based sexuality intervention for this patient and carer group that has potential for broader translation into community and acute health care settings. This approach will also have broader application for chronic disease self management for other health conditions.
Kidney transplantation is a life-saving treatment for most people with end-stage kidney disease. For some people, however, it causes more harm than good. We will clarify which individuals will benefit from transplantation by personalising information on predicting potential outcomes after transplantation. We will use this to develop a decision tool to help doctors and patients make these challenging and irreversible decisions. This will maximise the benefits from this precious resource.
Cardiovascular Disease; Priorities And Outcomes For People With Chronic And End Stage Kidney Disease
Funder
National Health and Medical Research Council
Funding Amount
$81,976.00
Summary
This thesis will investigate the patterns, causes and effects of heart disease in chronic kidney disease patients; how heart disease impacts on hospital admission patterns and mortality over time. We will explore the relationship between cognition, cardiovascular and kidney disease; the impact on patient outcomes and quality of life. Finally, we will explore how current research funding reflects disease burden, research output and the stated priorities of patients with chronic kidney disease.
New Antimalarial Drug Leads Targeting Multiple Species And Life Cycle Stages
Funder
National Health and Medical Research Council
Funding Amount
$818,477.00
Summary
Malaria causes ~200 million clinical cases and >430,000 deaths annually. Prevention and treatment relies on drugs, however malaria parasite drug resistance is an enormous problem. To address this issue, and aim towards eliminating malaria, we need to develop new drugs. This project addresses this important health need by investigating the ability of new chemical compounds, developed at CSIRO, to kill human-infecting malaria parasites during different parts of their complicated lifecycles.
Targeted Nanoparticle Delivery Of Agents To The Placenta To Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Preeclampsia, one of the most serious complications of pregnancy, affects around 3-8% of all pregnancies. Sadly, there is no treatment. We have developed a new technique to deliver treatments only to the placenta, sparing the mother and baby from side effects. We will test whether this technique can treat the source of preeclampsia, the placenta, in mouse models and human tissue samples in the laboratory. This work may offer possibilities of new treatments to other pregnancy complications.
Development Of Novel Therapeutics To Prevent Or Treat Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
Preeclampsia, a major pregnancy complication, affects ~3-8% of pregnancies. There is no cure. We have developed new strategies to tackle the disease, including delivery of agents specifically to the placenta and repurposing drugs safe in pregnancy. We will test whether these strategies can quench disease in models developed in our laboratory, and examine samples from women who participated in clinical trial to treat preeclampsia. This offers new possibilities in the management of preeclampsia.
Bench To Beside Translational Studies To Develop Treatments For Preeclampsia
Funder
National Health and Medical Research Council
Funding Amount
$265,138.00
Summary
Preeclampsia is a common, devastating complication of pregnancy responsible for the loss of countless mothers and babies. There is no medical treatment. Excitingly we have identified 2 medications, safe in pregnancy: metformin and sulfasalazine that may treat this disease. We plan to introduce these medications into the clinic to see whether they may be an effective treatment for preeclampsia. If successful, these medications have the potential to improve the lives of women and babies globally.